Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 16, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,000,000 ordinary shares of 25 pence each.
- Purchase Price: 1,455.24 pence per share.
- Treasury Holdings: 141,663,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,819,043,649 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the open market purchase of 2,000,000 shares on December 16, 2005. This action was executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005. The purchased shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (2,000,000 shares at 1,455.24 pence) against the company's cash position in broader financial reports.
- Confirm the updated share count of 5,819,043,649 in issue for earnings per share calculations.
- Review the remaining authorization for share buybacks under the May 25, 2005 shareholder mandate.